Latest News
Theramex Acquires Commercial Rights for Merck´s Oral Contraceptive Zoely
Friday 24 January 2020

24 January 2020 - UK-based harmaceutical company Theramex has entered into a definitive agreement to acquire further rights to patented oral contraceptive, Zoely from MSD, a tradename of Merck and Co., Inc. (NYSE: MRK), to build on its portfolio of treatment options for women, the company said.
Terms of the transaction were not disclosed.
Theramex currently markets Zoely in 11 European countries, and this transaction will bring the total number of markets up to more than 50 on a global basis.
MSD retains rights in the United States and Canada.
Theramex is a speciality pharmaceutical company dedicated to women and their health.
With a portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, Theramex supports women at every stage of their lives.
Date Published: 24/01/2020
Target: Zoely
Country: USA
Sector: Pharmaceuticals
Type: Corporate acquisition
Status: Agreed
Vendor: MSD
Buyer: Theramex
Terms of the deal were not disclosed